within Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BJ02_Liraglutide;

model Liraglutide
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C(
    weight = 70,
    F = 1,
    Cl = 2.5000000000000004e-07,
    adminDuration = 600,
    adminMass = 0.6 / 1000000,
    adminCount = 1,
    Vd = 0.013,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Liraglutide</td></tr><tr><td>ATC code:</td><td>A10BJ02</td></tr><td>route:</td><td>subcutaneous</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>0.6</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>13</td><td>L</td></tr>
    <tr><td>clearance:</td><td>0.9</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Liraglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist used primarily for the treatment of type 2 diabetes mellitus and as an anti-obesity agent. It is approved for use in adults and pediatric patients for glycemic control and for chronic weight management.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters determined in adult healthy subjects and patients with type 2 diabetes following subcutaneous administration.</p><h4>References</h4><ol><li><p>Watson, E, et al., &amp; Ingwersen, SH (2010). Population pharmacokinetics of liraglutide, a once-daily human glucagon-like peptide-1 analog, in healthy volunteers and subjects with type 2 diabetes, and comparison to twice-daily exenatide. <i>Journal of clinical pharmacology</i> 50(8) 886–894. DOI:<a href=\"https://doi.org/10.1177/0091270009354996\">10.1177/0091270009354996</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/20133507/\">https://pubmed.ncbi.nlm.nih.gov/20133507</a></p></li><li><p>Mastrandrea, LD, et al., &amp; Riesenberg, RA (2019). Liraglutide effects in a paediatric (7-11 y) population with obesity: A randomized, double-blind, placebo-controlled, short-term trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics. <i>Pediatric obesity</i> 14(5) e12495–None. DOI:<a href=\"https://doi.org/10.1111/ijpo.12495\">10.1111/ijpo.12495</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/30653847/\">https://pubmed.ncbi.nlm.nih.gov/30653847</a></p></li><li><p>Danne, T, et al., &amp; Kordonouri, O (2017). Liraglutide in an Adolescent Population with Obesity: A Randomized, Double-Blind, Placebo-Controlled 5-Week Trial to Assess Safety, Tolerability, and Pharmacokinetics of Liraglutide in Adolescents Aged 12-17 Years. <i>The Journal of pediatrics</i> 181 146–153.e3. DOI:<a href=\"https://doi.org/10.1016/j.jpeds.2016.10.076\">10.1016/j.jpeds.2016.10.076</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/27979579/\">https://pubmed.ncbi.nlm.nih.gov/27979579</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.A.A10BJ02 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Liraglutide;
